Special Issue

Urogenital Cancers: Diagnostic, Predictive, and Prognostic Markers

Message from the Guest Editor

Urogenital cancers include urothelial cancer, renal cell carcinoma, prostate cancer, testicular cancer, and other types of malignancies arising from retroperitoneal organs. There are still unsolved problems in early diagnosis, treatment selection, and precision medicine in this field. The forthcoming Special Issue will welcome submissions on, but not limited to, the following topics:

- Morbidity risk factors
- Non-invasive detection biomarkers (focusing on early detection is preferred)
- Novel DNA, RNA, protein biomarkers
- Novel systemic inflammation markers and nutritional markers such as the NLR, CRP, and GPS
- Novel radiographic markers
- Histological variants and their clinical impact
- Predictors of treatment responses
- Precision medicine
- Immunotherapy including immune check point inhibitors
- Decreasing morbidity risk, recurrence risk, and progression risk
- Upstaging in surgical specimens: gap between clinical stage and pathological stage
- Interpretation of cancer screening trials such as PSA screening in prostate cancer and urianalysis screening for bladder cancer

Guest Editor

Dr. Makito Miyake

Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan

Deadline for manuscript submissions

closed (30 November 2019)



Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



mdpi.com/si/25998

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

mdpi.com/journal/diagnostics





Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

